Meeting
2023 ASCO Annual Meeting
AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.
Authors
Eileen Mary O'Reilly
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY
Eileen Mary O'Reilly , Zev A. Wainberg , Colin D. Weekes , Muhammad Furqan , Pashtoon Murtaza Kasi , Craig E. Devoe , Alexis Diane Leal , Vincent Chung , James Perry , Lochana Seenappa , Lisa McNeil , Esther Welkowsky , Peter DeMuth , Christopher M. Haqq , Shubham Pant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT04853017
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2528)
DOI
10.1200/JCO.2023.41.16_suppl.2528
Abstract #
2528
Poster Bd #
370
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli
Poster
2024 ASCO Annual Meeting
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.
First Author: Susanna Varkey Ulahannan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.
First Author: Ecaterina Elena Dumbrava
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001.
First Author: Vivek Subbiah